Agreements reached under this partnership
Business alliance- 1
Initiation of Phase 1 clinical trials for [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155, HER2-targeted radioligand therapies (RLTs) developed using our platform system, PDPS®, under the joint research and development agreement between the 2 companies signed in 2019
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The milestone fee is expected to be recognized as revenue in the third quarter of the fiscal year ending December 2026. It has already been incorporated into the earnings forecast for the fiscal year ending December 2026, and there will be no change to the earnings forecast. The amount is undisclosed under the agreement with Novartis.
| Item | Details |
|---|---|
| Name of alliance partner | Novartis Pharma AG |
| Alliance partner's location | Switzerland |
| Type of alliance | Business alliance |
| Details of the alliance | Initiation of Phase 1 clinical trials for [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155, HER2-targeted radioligand therapies (RLTs) developed using our platform system, PDPS®, under the joint research and development agreement between the 2 companies signed in 2019 |
| Contract Date | 2019 (date Not disclosed) |
| Alliance start date | Phase 1 clinical trials initiated (start date Not disclosed) |
| Impact on Business Performance | The milestone fee is expected to be recognized as revenue in the third quarter of the fiscal year ending December 2026. It has already been incorporated into the earnings forecast for the fiscal year ending December 2026, and there will be no change to the earnings forecast. The amount is undisclosed under the agreement with Novartis. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This is because Novartis initiated Phase 1 clinical trials for [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155, developed using our PDPS® under the joint research and development agreement between the 2 companies signed in 2019.